Katharine Hall Thomas1,2, Robert A Ramirez2,3. 1. Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA. 2. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 3. Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA.
Abstract
BACKGROUND: Leptomeningeal disease (LMD) is a complication that results from solid tumor metastasis. Prognosis is extremely poor. As therapeutic options for solid tumors improve, the rate of LMD continues to increase. Until recently, treatment has been limited to radiation therapy, intrathecal chemotherapy, and systemic chemotherapy, with an overall survival of 2-3 months. Targeted molecular therapy and immunotherapies are promising new options for increasing overall survival and clinical improvement; however, optimal clinical management remains unknown. METHODS: In this review, we discuss targeted molecular therapy and immunotherapy treatment options for LMD resulting from primary lung, breast, and melanoma tumors. In addition, we summarize dosing strategies, overall survival, clinical outcomes, and novel approaches to treatment. RESULTS: Our review indicates a deficiency in the current literature. Presently, intrathecal trastuzumab administration may be an effective option for patients with HER2-positive breast cancer. BRAF inhibitors and cytotoxic T lymphocyte-associated antigen-4 targets have shown promising results in LMD resulting from melanoma. Finally, tyrosine kinase inhibitors may increase overall survival in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. Pulsatile drug administration or dual therapy may be beneficial for patients who progress to LMD while being treated with EGFR targets for their primary malignancy. CONCLUSION: Targeted molecular therapy and immunotherapy in LMD may provide favorable treatment options. Current literature is lacking in safety, efficacy, and overall response rates from the use of targeted therapy. Research is needed to draw significant conclusions about the most appropriate therapy for patients with LMD.
BACKGROUND: Leptomeningeal disease (LMD) is a complication that results from solid tumor metastasis. Prognosis is extremely poor. As therapeutic options for solid tumors improve, the rate of LMD continues to increase. Until recently, treatment has been limited to radiation therapy, intrathecal chemotherapy, and systemic chemotherapy, with an overall survival of 2-3 months. Targeted molecular therapy and immunotherapies are promising new options for increasing overall survival and clinical improvement; however, optimal clinical management remains unknown. METHODS: In this review, we discuss targeted molecular therapy and immunotherapy treatment options for LMD resulting from primary lung, breast, and melanoma tumors. In addition, we summarize dosing strategies, overall survival, clinical outcomes, and novel approaches to treatment. RESULTS: Our review indicates a deficiency in the current literature. Presently, intrathecal trastuzumab administration may be an effective option for patients with HER2-positive breast cancer. BRAF inhibitors and cytotoxic T lymphocyte-associated antigen-4 targets have shown promising results in LMD resulting from melanoma. Finally, tyrosine kinase inhibitors may increase overall survival in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. Pulsatile drug administration or dual therapy may be beneficial for patients who progress to LMD while being treated with EGFR targets for their primary malignancy. CONCLUSION: Targeted molecular therapy and immunotherapy in LMD may provide favorable treatment options. Current literature is lacking in safety, efficacy, and overall response rates from the use of targeted therapy. Research is needed to draw significant conclusions about the most appropriate therapy for patients with LMD.
Authors: Priscilla K Brastianos; Harry C Brastianos; Wesley Hsu; Daniel M Sciubba; Thomas Kosztowski; Betty M Tyler; Violette Renard Recinos; Peter Burger; Stuart A Grossman Journal: J Neurooncol Date: 2011-07-26 Impact factor: 4.130
Authors: Ulrich Herrlinger; Heike Förschler; Wilhelm Küker; Richard Meyermann; Michael Bamberg; Johannes Dichgans; Michael Weller Journal: J Neurol Sci Date: 2004-08-30 Impact factor: 3.181
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Heike Niessner; Andrea Forschner; Bernhard Klumpp; Jürgen B Honegger; Maria Witte; Antje Bornemann; Reinhard Dummer; Annemarie Adam; Jürgen Bauer; Ghazaleh Tabatabai; Keith Flaherty; Tobias Sinnberg; Daniela Beck; Ulrike Leiter; Cornelia Mauch; Alexander Roesch; Benjamin Weide; Thomas Eigentler; Dirk Schadendorf; Claus Garbe; Dagmar Kulms; Leticia Quintanilla-Martinez; Friedegund Meier Journal: Cancer Med Date: 2013-02-03 Impact factor: 4.452
Authors: Timothy K Nguyen; Arjun Sahgal; Jay Detsky; Eshetu G Atenafu; Sten Myrehaug; Chia-Lin Tseng; Zain Husain; Chris Heyn; Pejman Maralani; Mark Ruschin; James Perry; Hany Soliman Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Paolo Palmisciano; Ali S Haider; Chibueze D Nwagwu; Waseem Wahood; Kenny Yu; Chibawanye I Ene; Barbara J O'Brien; Salah G Aoun; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh Journal: Anticancer Res Date: 2021-11 Impact factor: 2.435
Authors: Ann-Kathrin Stoppek; Sied Kebir; Andreas Junker; Kathy Keyvani; Stefan Zülow; Lazaros Lazaridis; Teresa Schmidt; Daniela Pierscianek; Martin Stuschke; Ulrich Sure; Christoph Kleinschnitz; Björn Scheffler; Lisa Zimmer; Martin Glas Journal: BMC Cancer Date: 2019-10-23 Impact factor: 4.430